in vivo News and Research

RSS

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Study shows how cocaine changes the shape and size of neuron rewards in mouse model

New research from Mount Sinai Medical Center in New York reveals that repeated exposure to cocaine decreases the activity of a protein necessary for normal functioning of the brain's reward system, thus enhancing the reward for cocaine use, which leads to addiction. Investigators were also able to block the ability of repeated cocaine exposure, to induce addiction.

23 Apr 2012

Scripps Florida scientist to develop new tests for aging and stress-associated diseases

A scientist from the Florida campus of The Scripps Research Institute has been awarded just over $1 million from the National Institutes of Health to develop a range of new tests that could lead to new treatments for a number of stress-associated and degenerative disorders of advancing age.

21 Apr 2012

SEBM announces winners of 2012 Best Paper Awards

SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.

21 Apr 2012

Potential for gallbladder tissue as source for multipotential stem cells

A new study presented today at the International Liver Congress- 2012 indicates the potential for gallbladder tissue (which is routinely discarded from organ donors and surgical interventions) to be a highly available candidate source for multipotential stem cells.

20 Apr 2012

Bruker introduces new products at Analytica 2012

At Analytica 2012, Bruker today announced several new product introductions for the research, industrial and applied markets, designed to deliver confident analyses with increased sensitivity, specificity and productivity, and to push the boundaries of advanced molecular and materials research applications.

18 Apr 2012

Allied Healthcare announces Coridon license to vector technology

Allied Healthcare Group (ASX: AHZ) has announced an update on the progress of Coridon, its investment company founded by Professor Ian Frazer and working on developing the next generation of vaccines. Included in these activities, Cordon has entered into a license agreement with Nature Technology Corporation (NTC) and has contracted VGXI Inc. in the US for production of clinical material for the Phase I study scheduled to begin later this year.

17 Apr 2012

T-FET biosensor can detect biomolecules at ultra-low concentrations

A new quantum mechanical-based biosensor designed by a team at University of California, Santa Barbara offers tremendous potential for detecting biomolecules at ultra-low concentrations, from instant point-of-care disease diagnostics, to detection of trace substances for forensics and security.

17 Apr 2012

Hydrophilic carbon cluster HADES can selectively kill brain cancer cells

Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.

17 Apr 2012

Florbetaben PET scan reliably identifies beta-Amyloid in the brain

Piramal Imaging SA, a newly formed subsidiary of Piramal Healthcare Limited, announced positive first results from a Phase III study that showed that PET imaging with florbetaben reliably detects beta-Amyloid in the brain during life with great accuracy and thus shows value as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease.

16 Apr 2012

Botanical formula controls aggressive human prostate tumors in mice

A non-toxic, botanical formula controls aggressive human prostate tumors in mice, according to a peer-reviewed study in the The International Journal of Oncology. Researchers at Indiana University, Methodist Research Institute, showed the prostate formula significantly suppresses tumor growth in aggressive, hormone-refractory (androgen-independent) human prostate cancer cells.

11 Apr 2012

Fatty acids fight cancer spread

Tiny agents found in omega-3 could potentially be used to block the path of primary cancer tumors, preventing the advance to secondary stage cancers according to pharmacy researchers at the University of Sydney.

9 Apr 2012

Presage Biosciences enters cancer research agreement with Millennium

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company.

7 Apr 2012

Delcath’s second generation CHEMOSAT system receives European CE Mark

Delcath Systems, Inc. today announced that the Company has received CE Mark approval for the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

6 Apr 2012

Reactivation of p53 may be a highly selective treatment modality for virally-induced lymphoma

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

4 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

Gbb38 protein helps explain how cells send many long-haul messages

As they work together to form body parts, cells in developing organisms communicate like workers at a construction site. The discovery of a new signaling molecule in flies by Brown University biologists not only helps explain how cells send many long-haul messages, but also provides new clues for researchers who study how human development goes awry, for instance in cases of cleft lip and palate.

3 Apr 2012

PET allows survival predictions in sarcoma after initial cycle of neoadjuvant chemo

An early Positron Emission Tomography (PET) response after the initial cycle of neoadjuvant chemotherapy can be used to predict increased survival in patients with soft tissue sarcomas, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

3 Apr 2012

Organovo 2011 total revenues increase 61% to $968,513

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today reported the financial results for the year ended December 31, 2011.

3 Apr 2012